Adavosertib Is Safe and Efficacious in CCNE1-Amplified Solid Tumors

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• CCNE1 gene amplification is a driver mutation in various solid tumors, often associated with poor prognosis.
• Targeting cell cycle regulation is a key strategy in cancer therapy.
• Adavosertib is a potent and selective inhibitor of Wee1 kinase, a regulator of cell cycle progression.

Purpose of the Study:

• To evaluate the safety and tolerability of adavosertib in patients with advanced solid tumors.
• To assess the antitumor efficacy of adavosertib in patients with CCNE1-amplified solid tumors.
• To identify potential biomarkers for response to adavosertib.

Main Methods:

• Phase I/II clinical trial design.
• Dose escalation and expansion cohorts.
• Tumor response assessment using RECIST criteria.
• Pharmacokinetic and pharmacodynamic analyses.
• Genomic profiling for CCNE1 amplification.

Main Results:

• Adavosertib was generally well-tolerated, with manageable side effects.
• Objective response rates were observed in patients with CCNE1-amplified tumors.
• Durable responses were noted in a subset of patients.
• Pharmacodynamic effects on cell cycle markers were consistent with Wee1 inhibition.

Conclusions:

• Adavosertib exhibits a favorable safety profile and promising antitumor activity in advanced CCNE1-amplified solid tumors.
• Wee1 inhibition represents a viable therapeutic approach for tumors with CCNE1 amplification.
• Further investigation in larger trials is warranted to confirm these findings.